Bookmark
Forward
QuickView for ceftazidime (compound)
PubChem
| Name: | Ceftazidime |
|---|---|
| PubChem Compound ID: | 2650 |
| Description: | Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. |
| Molecular formula: | C22H22N6O7S2 |
| Molecular weight: | 546.578 g/mol |
DrugBank
Identification
| Name: | Ceftazidime |
|---|---|
| Name (isomeric): | DB00438 |
| Drug Type: | small molecule |
| Description: | Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. |
| Brand: | Ceptaz, Fortaz, Ceftazidime pentahydrate, Tazicef, Ceftazidimum [INN-Latin], Pentacef, Tazidime In Plastic Container, Ceftazidima [INN-Spanish], Fortaz In Plastic Container, Ceftazidime Sodium In Plastic Container, Tazidime |
| Category: | Cephalosporins, Anti-Bacterial Agents |
| CAS number: | 78439-06-2 |
Pharmacology
| Indication: | For the treatment of patients with infections caused by susceptible strains of organisms in the following diseases: lower respiratory tract infections,skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra abdominal infections (including peritonitis), and central nervous system infections (including meningitis). |
|---|---|
| Pharmacology: |
Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration. Ceftazidime is bactericidal in action exerting its effect by inhibition of enzymes responsible for cell-wall synthesis, primarily penicillin binding protein 3 (PBP3). A wide range of gram-negative organisms is susceptible to ceftazidime in vitro, i...
show more » |
| Mechanism of Action: | The bactericidal activity of ceftazidime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). |
| Absorption: | The absorption of ceftazidime is directly proportional to the size of the dose. |
| Protein binding: | < 10% |
| Route of elimination: | The elimination of ceftazidime by the kidneys resulted in high therapeutic concentrations in the urine. |
| Half Life: | Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function. |
| Clearance: | 115 mL/min |
| Toxicity: | Ceftazidime overdosage has occurred in patients with renal failure. Reactions have included seizure activity, encephalopathy, asterixis, neuromuscular excitability, and coma. |
| Affected organisms: | Enteric bacteria and other eubacteria |
Interactions
| Drug interaction: |
|
|---|
Targets
Transporters
